Compare NTIC & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | IBIO |
|---|---|---|
| Founded | 1970 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 72.2M |
| IPO Year | 1996 | 2009 |
| Metric | NTIC | IBIO |
|---|---|---|
| Price | $8.58 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 4.1K | ★ 1.1M |
| Earning Date | 04-09-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $84,234,474.00 | N/A |
| Revenue This Year | $11.40 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $280.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.77 | $0.56 |
| 52 Week High | $10.80 | $4.19 |
| Indicator | NTIC | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 31.79 |
| Support Level | $7.32 | $1.70 |
| Resistance Level | $8.58 | $1.81 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 1.32 | 22.05 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.